Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENTER: Erlotinib + WBRT for NSCLC Brain Metastases
NCT01887795Phase 3Completed
- Start
- Aug 2013
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of erlotinib in non-small cell lung cancer (NSCLC), brain metastases. Started Aug 2013; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)brain metastases
Beyond the preview
Go deeper on NCT01887795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01887795.